. 2018 Aug; 15(11):694-708.
doi: 10.1038/s41571-018-0081-4.

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

Gonzalo Recondo 1 Francesco Facchinetti 2 Ken A Olaussen 1 Benjamin Besse 1 Luc Friboulet 3 
  • PMID: 30108370
  •     100 citations


The traditional approach to the treatment of patients with advanced-stage non-small-cell lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations has been the sequential administration of therapies (sequential treatment approach), in which patients first receive first-generation tyrosine-kinase inhibitors (TKIs), which are eventually replaced by next-generation TKIs and/or chemotherapy upon disease progression, in a decision optionally guided by tumour molecular profiling. In the past few years, this strategy has been challenged by clinical evidence showing improved progression-free survival, improved intracranial disease control and a generally favourable toxicity profile when next-generation EGFR and ALK TKIs are used in the first-line setting. In this Review, we describe the existing preclinical and clinical evidence supporting both treatment strategies - the 'historical' sequential treatment strategy and the use of next-generation TKIs - as frontline therapies and discuss the suitability of both strategies for patients with EGFR-driven or ALK-driven NSCLC.

Targeting anaplastic lymphoma kinase in neuroblastoma.
Ganesh Umapathy, Patricia Mendoza-Garcia, Bengt Hallberg, Ruth H Palmer.
APMIS, 2019 Feb 26; 127(5). PMID: 30803032    Free PMC article.
Phase I trials as valid therapeutic options for patients with cancer.
Jacob J Adashek, Patricia M LoRusso, David S Hong, Razelle Kurzrock.
Nat Rev Clin Oncol, 2019 Sep 04; 16(12). PMID: 31477881    Free PMC article.
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
Alessandro Leonetti, Sugandhi Sharma, +3 authors, Marcello Tiseo.
Br J Cancer, 2019 Oct 01; 121(9). PMID: 31564718    Free PMC article.
Highly Cited. Review.
Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date.
Francesco Facchinetti, Luc Friboulet.
Lung Cancer (Auckl), 2019 Oct 02; 10. PMID: 31572036    Free PMC article.
Increased Expression and Activation of FAK in Small-Cell Lung Cancer Compared to Non-Small-Cell Lung Cancer.
Frank Aboubakar Nana, Delphine Hoton, +7 authors, Sebahat Ocak.
Cancers (Basel), 2019 Oct 30; 11(10). PMID: 31658694    Free PMC article.
Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target.
Frank Aboubakar Nana, Marie Vanderputten, Sebahat Ocak.
Cancers (Basel), 2019 Nov 02; 11(11). PMID: 31671774    Free PMC article.
Long Noncoding RNA LINC01116 Contributes to Gefitinib Resistance in Non-small Cell Lung Cancer through Regulating IFI44.
He Wang, Binbin Lu, +4 authors, Zhaoxia Wang.
Mol Ther Nucleic Acids, 2019 Dec 17; 19. PMID: 31841994    Free PMC article.
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
Gonzalo Recondo, Laura Mezquita, +38 authors, Luc Friboulet.
Clin Cancer Res, 2019 Oct 06; 26(1). PMID: 31585938    Free PMC article.
Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
Barbara Melosky, Rosalyn Juergens, +5 authors, Quincy Chu.
Oncologist, 2019 May 30; 25(1). PMID: 31138727    Free PMC article.
Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs.
Yuan Tang, Nanying Che, +8 authors, Dongmei Lin.
J Cancer Res Clin Oncol, 2019 Nov 07; 146(2). PMID: 31696302
Metabolic regulation of cell growth and proliferation.
Jiajun Zhu, Craig B Thompson.
Nat Rev Mol Cell Biol, 2019 Apr 13; 20(7). PMID: 30976106    Free PMC article.
Highly Cited. Review.
5-HT7 Receptor Contributes to Proliferation, Migration and Invasion in NSCLC Cells.
Xiaohui Du, Ting Wang, +5 authors, Jungang Xie.
Onco Targets Ther, 2020 Mar 27; 13. PMID: 32210580    Free PMC article.
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.
Peter T Harrison, Simon Vyse, Paul H Huang.
Semin Cancer Biol, 2019 Sep 29; 61. PMID: 31562956    Free PMC article.
Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.
Peng Song, Xiaoxia Cui, +14 authors, Li Zhang.
Thorac Cancer, 2019 Apr 25; 10(5). PMID: 31016875    Free PMC article.
Next-Generation Cancer-Specific Hybrid Theranostic Nanomaterials: MAGE-A3 NIR Persistent Luminescence Nanoparticles Conjugated to Afatinib for In Situ Suppression of Lung Adenocarcinoma Growth and Metastasis.
Ming-Hsien Chan, Wen-Tse Huang, +2 authors, Michael Hsiao.
Adv Sci (Weinh), 2020 May 10; 7(9). PMID: 32382487    Free PMC article.
Integration of Comprehensive Genomic Analysis and Functional Screening of Affected Molecular Pathways to Inform Cancer Therapy.
George Vasmatzis, Minetta C Liu, +12 authors, Panos Z Anastasiadis.
Mayo Clin Proc, 2019 Nov 07; 95(2). PMID: 31685261    Free PMC article.
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Miriam Grazia Ferrara, Vincenzo Di Noia, +8 authors, Emilio Bria.
Cancers (Basel), 2020 May 14; 12(5). PMID: 32397295    Free PMC article.
Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC.
Dantong Sun, Yan Zhu, +4 authors, Helei Hou.
Mol Med, 2020 Jul 03; 26(1). PMID: 32611363    Free PMC article.
Predicting EGFR mutation subtypes in lung adenocarcinoma using 18F-FDG PET/CT radiomic features.
Qiufang Liu, Dazhen Sun, +5 authors, Shaoli Song.
Transl Lung Cancer Res, 2020 Jul 18; 9(3). PMID: 32676319    Free PMC article.
Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis.
Fei Chen, Naifei Chen, Yu Yu, Jiuwei Cui.
Front Oncol, 2020 Jul 28; 10. PMID: 32714857    Free PMC article.
Systematic Review.
The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation.
Shang-Gin Wu, Chong-Jen Yu, James Chih-Hsin Yang, Jin-Yuan Shih.
Ther Adv Med Oncol, 2020 Aug 28; 12. PMID: 32843903    Free PMC article.
Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers.
Sebastian Mondaca, Michael Offin, +10 authors, Maria E Arcila.
Acta Oncol, 2019 Jul 28; 58(11). PMID: 31347936    Free PMC article.
ZNF251 promotes the progression of lung cancer by activating ERK signaling.
Chenxi Zhong, Chunji Chen, Feng Yao, Wentao Fang.
Cancer Sci, 2020 Jun 27; 111(9). PMID: 32589309    Free PMC article.
Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer.
Mathieu Chevallier, Petros Tsantoulis, Alfredo Addeo, Alex Friedlaender.
Cancer Genomics Proteomics, 2020 Aug 30; 17(5). PMID: 32859638    Free PMC article.
Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma.
Wen-Lung Su, Shih-Chang Chuang, +7 authors, Kung-Kai Kuo.
Cancer Biomark, 2020 May 12; 28(3). PMID: 32390596    Free PMC article.
Modulating EGFR-MTORC1-autophagy as a potential therapy for persistent fetal vasculature (PFV) disease.
Meysam Yazdankhah, Peng Shang, +13 authors, Debasish Sinha.
Autophagy, 2019 Aug 30; 16(6). PMID: 31462148    Free PMC article.
Look around your target: a new approach to early diagnosis of lung cancer.
Vito R Papapietro, Gianluca Milanese, +2 authors, Mario Silva.
Ann Transl Med, 2019 Jan 08; 6(Suppl 1). PMID: 30613652    Free PMC article.
Liquid biopsy guided precision therapy for lung cancers.
Chongrui Xu, Michael Offin, Paul K Paik, Bob T Li.
J Thorac Dis, 2019 Jan 12; 10(Suppl 33). PMID: 30631586    Free PMC article.
Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?
Alessandro Leonetti, Francesco Facchinetti, Marcello Tiseo.
Ann Transl Med, 2019 Feb 12; 6(Suppl 2). PMID: 30740431    Free PMC article.
Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology.
Christina Alidousty, Till Baar, +5 authors, Anne Maria Schultheis.
J Thorac Dis, 2019 Feb 19; 11(Suppl 1). PMID: 30775023    Free PMC article.
Resistances to EGFR tyrosine kinase inhibitors in lung cancer-how to routinely track them in a molecular pathology laboratory?
Véronique Hofman, Paul Hofman.
J Thorac Dis, 2019 Feb 19; 11(Suppl 1). PMID: 30775029    Free PMC article.
SELECTing adjuvant treatment in early stage epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer.
Fabrizio Tabbò, Maria Lucia Reale, +2 authors, Francesco Guerrera.
Ann Transl Med, 2019 Jun 18; 7(9). PMID: 31205908    Free PMC article.
Successful salvage surgery following multimodal therapy in a patient who harboured ALK-rearranged advanced lung adenocarcinoma with multiple organ metastases.
Yoshitsugu Horio, Tetsuya Mizuno, +3 authors, Toyoaki Hida.
Respirol Case Rep, 2019 Jul 10; 7(7). PMID: 31285825    Free PMC article.
PD-1/PD-L1 Inhibitors for Non-Small Cell Lung Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management.
Marianne J Davies.
J Adv Pract Oncol, 2019 Mar 01; 10(Suppl 1). PMID: 33014515    Free PMC article.
Long non-coding RNA CASC9 promotes gefitinib resistance in NSCLC by epigenetic repression of DUSP1.
Zhenyao Chen, Qinnan Chen, +7 authors, Zhaoxia Wang.
Cell Death Dis, 2020 Oct 16; 11(10). PMID: 33056982    Free PMC article.
Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study.
Pierre-Jean Lamy, Paul van der Leest, +8 authors, Catherine Alix-Panabières.
Cancers (Basel), 2020 Oct 22; 12(10). PMID: 33081150    Free PMC article.
HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer.
Toshimitsu Yamaoka, Junji Tsurutani, Hironori Sagara, Tohru Ohmori.
Transl Lung Cancer Res, 2020 Nov 20; 9(5). PMID: 33209639    Free PMC article.
New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives.
Ramon Andrade de Mello, Nathália Moisés Neves, +3 authors, Victor André de Almeida Zia.
J Clin Med, 2020 Nov 07; 9(11). PMID: 33153004    Free PMC article.
Value of PET/MRI for assessing tumor resectability in NSCLC-intra-individual comparison with PET/CT.
Michael Messerli, Felipe de Galiza Barbosa, +8 authors, Patrick Veit-Haibach.
Br J Radiol, 2018 Sep 14;. PMID: 30209954    Free PMC article.
Fluorescence in Situ Hybridization (FISH) for Detecting Anaplastic Lymphoma Kinase (ALK) Rearrangement in Lung Cancer: Clinically Relevant Technical Aspects.
Zhenya Tang, Lu Wang, Guilin Tang, L Jeffrey Medeiros.
Int J Mol Sci, 2019 Aug 16; 20(16). PMID: 31412611    Free PMC article.
Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise.
Daphné Morel, Daniel Jeffery, +2 authors, Sophie Postel-Vinay.
Nat Rev Clin Oncol, 2019 Oct 02; 17(2). PMID: 31570827
Highly Cited. Review.
[Advances in Drug Resistance Mechanisms and Prognostic Markers of Targeted Therapy in ALK-positive Non-small Cell Lung Cancer].
Shasha Wang, Yuankai Shi, Xiaohong Han.
Zhongguo Fei Ai Za Zhi, 2020 Nov 19; 23(11). PMID: 33203201    Free PMC article.
In vitro and in vivo Study of a Novel Liposome-Mediated Dual Drug Delivery for Synergistic Lung Cancer Therapy via Oral Administration.
Qi Zhou, Zhiqiang Fu.
Onco Targets Ther, 2020 Dec 18; 13. PMID: 33328741    Free PMC article.
Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer.
Shaocong Wu, Min Luo, +7 authors, Liwu Fu.
Mol Cancer, 2021 Jan 20; 20(1). PMID: 33461557    Free PMC article.
Licochalcone A inhibits EGFR signalling and translationally suppresses survivin expression in human cancer cells.
Feng Gao, Ming Li, +3 authors, Wei Li.
J Cell Mol Med, 2020 Nov 29; 25(2). PMID: 33247550    Free PMC article.
Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won.
Fabrizio Tabbò, Maria Lucia Reale, Paolo Bironzo, Giorgio V Scagliotti.
Transl Lung Cancer Res, 2021 Jan 26; 9(6). PMID: 33489817    Free PMC article.
ALK phosphorylates SMAD4 on tyrosine to disable TGF-β tumour suppressor functions.
Qianting Zhang, Mu Xiao, +23 authors, Xin-Hua Feng.
Nat Cell Biol, 2019 Jan 22; 21(2). PMID: 30664791
An intergenic region ALK fusion identified by DNA sequencing and validated by IHC in an early-stage lung adenocarcinoma.
Yawei Dou, Qianqian Duan, +2 authors, Hongtao Wang.
J Cancer Res Clin Oncol, 2021 Feb 06; 147(6). PMID: 33544200
First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer.
Po-Lan Su, Chian-Wei Chen, +2 authors, Wu-Chou Su.
Thorac Cancer, 2020 Dec 19; 12(3). PMID: 33336895    Free PMC article.
Identification and Validation of Efficacy of Immunological Therapy for Lung Cancer From Histopathological Images Based on Deep Learning.
Yachao Yang, Jialiang Yang, +4 authors, Kaimei Huang.
Front Genet, 2021 Feb 27; 12. PMID: 33633793    Free PMC article.
HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs.
Sho Watanabe, Yasushi Goto, +7 authors, Yosuke Togashi.
Thorac Cancer, 2021 Jan 21; 12(5). PMID: 33471376    Free PMC article.
Analysis of the differences in lung cancer research trends between China and the United States based using project funding data.
Yuansheng Zheng, Yiwei Huang, +9 authors, Qun Wang.
Ann Transl Med, 2021 Mar 13; 9(3). PMID: 33708842    Free PMC article.
ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non-small cell lung cancer.
Helei Hou, Dantong Sun, +2 authors, Xiaochun Zhang.
Thorac Cancer, 2021 Jan 29; 12(6). PMID: 33506568    Free PMC article.
Cost-effectiveness analysis of first-line treatments for advanced epidermal growth factor receptor-mutant non-small cell lung cancer patients.
Wen-Qian Li, Ling-Yu Li, Jin Chai, Jiu-Wei Cui.
Cancer Med, 2021 Feb 25; 10(6). PMID: 33626238    Free PMC article.
Treatment Patterns and Survival of Patients With Advanced Non-Small Cell Lung Cancer Guided by Comprehensive Genomic Profiling: Real-World Single-Institute Study in China.
Weize Lv, Hua Cheng, +8 authors, Xiaofeng Pei.
Front Oncol, 2021 Mar 30; 11. PMID: 33777783    Free PMC article.
TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.
Emiliano Cocco, Ji Eun Lee, +31 authors, Maurizio Scaltriti.
Cancer Discov, 2020 Oct 03; 11(1). PMID: 33004339    Free PMC article.
Trichostatin A downregulates bromodomain and extra-terminal proteins to suppress osimertinib resistant non-small cell lung carcinoma.
Yuting Meng, Xixi Qian, +5 authors, Xuerong Wang.
Cancer Cell Int, 2021 Apr 17; 21(1). PMID: 33858423    Free PMC article.
Triple administration of osimertinib followed by chemotherapy for advanced lung adenocarcinoma: A case report.
Xu-Yan Hu, Yu-Cheng Fei, +2 authors, Dong-Lai Lv.
World J Clin Cases, 2021 Apr 24; 9(11). PMID: 33889629    Free PMC article.
Oncogenic driver mutations in non-small cell lung cancer: Past, present and future.
Mathieu Chevallier, Maxime Borgeaud, Alfredo Addeo, Alex Friedlaender.
World J Clin Oncol, 2021 May 08; 12(4). PMID: 33959476    Free PMC article.
Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma.
Tuo Zhang, Beibei Sun, +12 authors, Feng Yao.
Transl Lung Cancer Res, 2021 May 21; 10(4). PMID: 34012798    Free PMC article.
Long-Term Survival of Over 6 Years with Afatinib Sequential Treatment in a Patient with EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Case Report.
Hai-Yan Tu, Yang-Si Li, +5 authors, Yi-Long Wu.
Clin Drug Investig, 2021 Apr 17; 41(5). PMID: 33861418    Free PMC article.
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group.
Raymond U Osarogiagbon, Diana Merino Vega, +11 authors, James L Wade.
Clin Cancer Res, 2021 Feb 11; 27(9). PMID: 33563637    Free PMC article.
Targeting EML4-ALK gene fusion variant 3 in thyroid cancer.
Mehtap Derya Aydemirli, Jaap D H van Eendenburg, +4 authors, Hans Morreau.
Endocr Relat Cancer, 2021 Apr 21; 28(6). PMID: 33878728    Free PMC article.
Ethacrynic Acid Enhances the Antitumor Effects of Afatinib in EGFR/T790M-Mutated NSCLC by Inhibiting WNT/Beta-Catenin Pathway Activation.
Xuehui Zhang, Chaoyuan Huang, +3 authors, Xiaoling Luo.
Dis Markers, 2021 Jun 15; 2021. PMID: 34122668    Free PMC article.
PKCδ-mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs.
Chia-Hung Chen, Bo-Wei Wang, +14 authors, Wei-Chien Huang.
Oncogene, 2021 Jun 23; 40(29). PMID: 34155348    Free PMC article.
Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.
Bin Yang, Li Zhou, +13 authors, Guangming Lu.
Respir Res, 2021 Jun 30; 22(1). PMID: 34183009    Free PMC article.
Targeting DNAJC19 overcomes tumor growth and lung metastasis in NSCLC by regulating PI3K/AKT signaling.
Ji Zhou, Yang Peng, +5 authors, Tao Ren.
Cancer Cell Int, 2021 Jul 05; 21(1). PMID: 34217321    Free PMC article.
Evaluation of the Lung Immune Prognostic Index in Non-Small Cell Lung Cancer Patients Treated With Systemic Therapy: A Retrospective Study and Meta-Analysis.
Litang Huang, Hedong Han, +7 authors, Yong Song.
Front Oncol, 2021 Jul 13; 11. PMID: 34249708    Free PMC article.
Systematic Review.
The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden.
Fredrik O L Nilsson, Sandra T Asanin, +4 authors, Sarah Smith.
Pharmacoeconomics, 2021 Jun 04; 39(8). PMID: 34080140    Free PMC article.
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis.
Giorgia Guaitoli, Marcello Tiseo, +2 authors, Francesco Facchinetti.
Transl Lung Cancer Res, 2021 Jul 24; 10(6). PMID: 34295687    Free PMC article.
Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
Suntae Kim, Ji Hye Im, +6 authors, Keon Wook Kang.
Oxid Med Cell Longev, 2021 Aug 10; 2021. PMID: 34367462    Free PMC article.
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer.
Nikolaus Magios, Farastuk Bozorgmehr, +16 authors, Petros Christopoulos.
Ther Adv Med Oncol, 2021 Aug 20; 13. PMID: 34408792    Free PMC article.
Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non-small-cell lung cancer harboring EGFR mutations: Results from a real-world study in South Korea.
Taeyun Kim, Tae Won Jang, +14 authors, Seong Hoon Yoon.
Cancer Med, 2021 Jul 15; 10(17). PMID: 34258882    Free PMC article.
Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors.
Xiaojing Du, Biwei Yang, +3 authors, Jinglin Xia.
Innovation (N Y), 2021 Sep 25; 2(2). PMID: 34557754    Free PMC article.
Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report.
Diego Enrico, Ludovic Lacroix, +19 authors, Benjamin Besse.
JTO Clin Res Rep, 2020 Mar 07; 1(2). PMID: 34589930    Free PMC article.
Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan.
Shang-Gin Wu, Wei-Yu Liao, +5 authors, Jin-Yuan Shih.
JTO Clin Res Rep, 2021 Oct 01; 2(2). PMID: 34589991    Free PMC article.
Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib.
Han Han, Shuai Li, +26 authors, Kwok-Kin Wong.
Cancer Res, 2021 Aug 13; 81(20). PMID: 34380634    Free PMC article.
Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.
Teng Li, Shouzheng Wang, +6 authors, Junling Li.
Thorac Cancer, 2021 Sep 23; 12(21). PMID: 34549528    Free PMC article.
HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy.
Jiadi Gan, Yihua Huang, +2 authors, Wenfeng Fang.
Onco Targets Ther, 2021 Nov 27; 14. PMID: 34824536    Free PMC article.
Bilateral acute anterior uveitis: a rare ocular side effect of erlotinib.
Sarah Chan, Elizabeth Ahern, Sarah Chaudhry, Brett Hughes.
BMJ Case Rep, 2019 Dec 18; 12(12). PMID: 31843782    Free PMC article.
Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib.
Zhen Chen, Danlei Yu, +2 authors, Shi-Yong Sun.
Oncogene, 2021 Oct 13; 40(49). PMID: 34635799    Free PMC article.
Contribution of the IdyllaTM System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations.
Constance Petiteau, Gwladys Robinet-Zimmermann, +8 authors, Guénaëlle Levallet.
Curr Oncol, 2021 Dec 14; 28(6). PMID: 34898548    Free PMC article.
Fatal Tumour Lysis Syndrome Induced by Brigatinib in a Lung Adenocarcinoma Patient Treated With Sequential ALK Inhibitors: A Case Report.
Yadong Wang, Tiange Wang, +10 authors, Naixin Liang.
Front Pharmacol, 2022 Jan 07; 12. PMID: 34987411    Free PMC article.
Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
Laird B Cameron, Nadia Hitchen, +4 authors, Vanessa Jordan.
Cochrane Database Syst Rev, 2022 Jan 08; 1. PMID: 34994987    Free PMC article.
Construction of a circRNA-miRNA-mRNA Regulated Pathway Involved in EGFR-TKI Lung Adenocarcinoma Resistance.
Chenyue Dai, Bing Liu, +5 authors, Yuanyuan Ma.
Technol Cancer Res Treat, 2021 Nov 27; 20. PMID: 34825849    Free PMC article.
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features.
Keiko Tanimura, Tadaaki Yamada, +22 authors, Koichi Takayama.
NPJ Precis Oncol, 2022 Jan 20; 6(1). PMID: 35042943    Free PMC article.
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.
Ming Yi, Xiaoli Zheng, +3 authors, Kongming Wu.
Mol Cancer, 2022 Jan 23; 21(1). PMID: 35062949    Free PMC article.
Targeting HSP90 Inhibits Proliferation and Induces Apoptosis Through AKT1/ERK Pathway in Lung Cancer.
Mengyuan Niu, Bin Zhang, +11 authors, Hongwei Wang.
Front Pharmacol, 2022 Feb 01; 12. PMID: 35095481    Free PMC article.
Allosteric Inhibition of the Epidermal Growth Factor Receptor.
Julie K L Sinclair, Wesley E Robertson, +2 authors, Alanna Schepartz.
Biochemistry, 2021 Feb 10; 60(7). PMID: 33557518    Free PMC article.
Successful erlotinib rechallenge in an EGFR-mutant metastatic non-small cell lung cancer patient with afatinib-induced drug rash with eosinophilia and systemic symptoms: A case report.
Chung-Fu Lin, Szu-Yu Liu, +2 authors, Po-Lan Su.
Thorac Cancer, 2021 Dec 18; 13(3). PMID: 34918465    Free PMC article.
Circ_0014235 confers Gefitinib resistance and malignant behaviors in non-small cell lung cancer resistant to Gefitinib by governing the miR-146b-5p/YAP/PD-L1 pathway.
Rong Niu, Dong Li, Jian Chen, Wentao Zhao.
Cell Cycle, 2021 Dec 18; 21(1). PMID: 34919024    Free PMC article.
Oncogenic Alterations in Histologically Negative Lymph Nodes Are Associated with Prognosis of Patients with Stage I Lung Adenocarcinoma.
Yiping Tian, Qian Lai, +8 authors, Dan Su.
Cancers (Basel), 2022 Feb 16; 14(3). PMID: 35159091    Free PMC article.
Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers.
Jill Kolesar, Spencer Peh, +9 authors, Mahadev Rao.
Mol Cancer, 2022 Feb 26; 21(1). PMID: 35209919    Free PMC article.
PHLDB2 Mediates Cetuximab Resistance via Interacting With EGFR in Latent Metastasis of Colorectal Cancer.
Maochao Luo, Zhao Huang, +26 authors, Hai-Ning Chen.
Cell Mol Gastroenterol Hepatol, 2021 Dec 25; 13(4). PMID: 34952201    Free PMC article.
An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study.
Po-Lan Su, Gee-Chen Chang, +7 authors, Yuh-Min Chen.
JTO Clin Res Rep, 2022 Mar 08; 3(3). PMID: 35252898    Free PMC article.
Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio for EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients Treated with First-Line EGFR-TKIs: A Large Population-Based Study and Literature Review.
Yuncui Gan, Jing Ren, +4 authors, Weimin Li.
Int J Gen Med, 2022 Apr 06; 15. PMID: 35378914    Free PMC article.
Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes.
Shideh Mirhadi, Shirley Tam, +24 authors, Ming-Sound Tsao.
Nat Commun, 2022 Apr 07; 13(1). PMID: 35383171    Free PMC article.
Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.
Fiorella Calabrese, Federica Pezzuto, +6 authors, Paul Hofman.
Int J Mol Sci, 2022 Apr 24; 23(8). PMID: 35456982    Free PMC article.
EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAFV600E mutation: a case report and review of literature.
Ran Zeng, Lifeng Luo, +6 authors, Yi Xiang.
Cancer Drug Resist, 2022 May 19; 4(4). PMID: 35582379    Free PMC article.
Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer.
Barbara Rath, Adelina Plangger, Gerhard Hamilton.
Cancer Drug Resist, 2020 Feb 28; 3(2). PMID: 35582610    Free PMC article.